Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia
- 276 Downloads
Case We report a case of simultaneous methemoglobinemia and hemolytic anemia, probably related to the use of rasburicase, in a child starting treatment for acute lymphoblastic leukemia (ALL). In addition, the patient developed symptoms of pancreatitis. All complications resolved after 3 days of supportive therapy. Conclusion Although usually well tolerated in pediatrics, physicians prescribing rasburicase should be aware of these possible life-threatening adverse reactions.
KeywordsClinical pharmacy Hemolytic anemia Methemoglobinemia Pancreatitis Pediatric hemato-oncology Rasburicase
Conflicts of interest
The authors have no conflicts of interest.
- 1.Ueng S. Rasburicase (Elitek): a novel agent for tumor lysis syndrome. Proc (Bayl Univ Med Cent). 2005;18(3):275–9.Google Scholar
- 3.Cairo MS. Prevention and treatment of hyperuricemia in hematological malignancies. Clin Lymphoma. 2002; Suppl 1:S26–31.Google Scholar
- 7.E-Compendium. Scientific Leaflet Fasturtec (in Flemish). Available from: http://www.ecompendium.be/. Accessed on 12 May 2010.
- 10.Identifying Adverse Drug Reactions. Available from http://qmweb.dads.state.tx.us/MedSim/Naranjo.htm. Accessed on 14 Apr 2010.